Sponsors (36)
The bill seeks to accelerate and clarify access to ALS and related rare‑disease therapies and improve oversight and coordination, but it does so without guaranteed funding and introduces regulatory, implementation, and cost uncertainties that could affect patient safety, stakeholder cooperation, and federal budgets.
People with ALS and other rare neurodegenerative diseases could get faster and more predictable access to investigational therapies because the bill expands which trials count, ties grant decisions to enrollment, and requires FDA planning and reporting.
Researchers and drug developers gain clearer statutory authority, eligibility criteria, and (through reporting/coordination) greater visibility into FDA priorities, helping align trials and investment decisions.
Congressional signals and required reports (including GAO analysis) increase the likelihood of informed oversight and evidence-based program improvements over time.
The bill does not specify funding levels or timelines, creating uncertainty about when programs will be implemented and raising the risk that new obligations will increase federal spending or require appropriations trade-offs for taxpayers.
Amendments to FDA-related standards and allowing planned or non‑enrolling phase 3 trials to count toward program criteria could increase reliance on weaker evidence and introduce safety or efficacy trade-offs for patients accessing experimental therapies.
Requesting interim trial data and additional reporting could impose financial and administrative burdens on manufacturers, risk disclosure of proprietary information, and discourage cooperation.
Based on analysis of 5 sections of legislative text.
Updates an ALS therapy-acceleration law by tightening grant renewal review (trial enrollment/interim data), clarifying trial definitions, requiring an FDA 5‑year action plan/report, and ordering a GAO review.
Introduced April 6, 2026 by Mike Quigley · Last progress April 6, 2026
Amends an existing law that speeds development of therapies for ALS and other rare neurodegenerative diseases by changing how grant renewals are reviewed, clarifying which clinical trials count for program purposes, requiring an updated FDA 5‑year action plan and public report, and ordering a GAO evaluation. It does not specify new funding amounts. The bill directs the FDA to publish an updated five‑year action plan and assessment within one year, and requires the Government Accountability Office to deliver a multi‑year report within four years, with changes intended to improve coordination with disease communities and to give program reviewers more information about trial enrollment and interim data when evaluating grants.